Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.24 USD | +1.20% | -9.18% | +165.73% |
05-10 | Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating | MT |
05-09 | Vera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+165.73% | 2.23B | |
+28.72% | 48.16B | |
-0.77% | 41.73B | |
+44.70% | 41.03B | |
-5.31% | 28.77B | |
+10.45% | 25.59B | |
-22.49% | 18.96B | |
+8.31% | 12.92B | |
+28.41% | 12.03B | |
-2.49% | 11.77B |
- Stock Market
- Equities
- VERA Stock
- News Vera Therapeutics, Inc.
- Raymond James Upgrades Vera Therapeutics to Strong Buy From Outperform, Raises PT to $37 From $29